Previous 10 | Next 10 |
BeyondSpring (NASDAQ: BYSI ) rises 2.7% and Kadmon Holdings (NYSE: KDMN ) also gains 2.7% after Nomura Instinet initiates coverage of the two companies at Buy. More news on: BeyondSpring Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, Re...
Aerie Pharmaceuticals (NASDAQ: AERI ) initiated with Neutral rating and $27 (6% upside) price target at Bank of America. More news on: Aurinia Pharmaceuticals Inc., BeyondSpring Inc., Cerecor Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Dr. James Tonra Promoted to Chief Scientific Officer Roland Liu Named Chief Commercial Officer for China Subsidiary NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceut...
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer reviewed journal Cancer Chemotherapy and Pharmacology published ...
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI) Q3 2019 Earnings Call Dec 18, 2019 , 8:00 a.m. ET Operator Continue reading
BeyondSpring Inc. (BYSI) Q3 2019 Earnings Conference Call December 18, 2019 8:00 A.M. ET Company Participants David Schemelia - Senior Vice President, KCSA Strategic Communications Lan Huang - Chairman and Chief Executive Officer Ramon Mohanlal - Executive Vice President of Resea...
BeyondSpring (NASDAQ: BYSI ): Q3 GAAP EPS of -$0.37 misses by $0.07 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 Plinabulin’s Anti-Cancer and CIN Prevention Mechanism Published in Peer Reviewed Journals NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the ...
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will host its third-quar...
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 Study 106 clinical trial design ...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...